FDA Brief

Warning letters Drugs

FDA warning letter to

Quality CDMO, Inc.

High riskIssued Sep 11, 2024Posted Sep 17, 2024Center for Drug Evaluation and Research (CDER)

FDA warned Quality CDMO that its prescription skin and scalp drugs are unapproved and lack FDA-approved applications.

What happened

FDA inspected Quality CDMO’s Fort Worth, TX drug manufacturing facility from June 12 to 16, 2023, and then reviewed the firm’s website and product labeling. FDA found five prescription drug products with labeled uses such as treating dermatitis, acne, dandruff, psoriasis, and skin cracks, but no FDA-approved applications were in effect for them.

What FDA found

  1. The five products are drugs because their labels say they treat diseases or affect the body.

    section 201(g)(1)(B) and/or (C) of the FD&C Act, 21 U.S.C. 321(g)(1)(B) and/or (C)
  2. FDA considers the products new drugs because they are not generally recognized as safe and effective for their labeled uses.

    section 201(p)(1) of the FD&C Act, 21 U.S.C. 321(p)(1)
  3. The firm introduced or delivered for introduction into interstate commerce these unapproved new drugs without an FDA-approved application.

    sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a)

What FDA wants

FDA tells the company to stop marketing all of the unapproved prescription drugs immediately and to contact CDER’s Drug Shortages Staff about any discontinuances or interruptions. It must respond in writing within 15 working days with corrective steps, supporting documents, and any eDRLS listing updates, or explain why it believes the products are not violations.

Who should pay attention

  • pharmacies and prescribers who buy these products
  • brands and distributors sourcing from Quality CDMO
  • other firms listing similar unapproved prescription skin drugs

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Jing Cheong Asia Inc. dba New York Tong Ren Tang

    New York Tong Ren Tang marketed unapproved new drugs, including eye drops, on its website.

    High risk
  4. Phuoc Loc Tho Herbals, Inc.

    FDA warned Phuoc Loc Tho Herbals that its herbal products are unapproved new drugs marketed with disease claims.

    High risk